MedTrace Logo

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

NCT07603856 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-05-22

No results posted yet for this study

Summary

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Conditions

Interventions

DRUG

Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)

Participant will receive an FDA approved immunotherapy according to usual routine practice.

DRUG

Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments)

Description something along the lines of Participant will receive an FDA approved chemotherapy according to usual routine practice.

RADIATION

Ablative Hypofractionated Radiotherapy

Participant will receive radiotherapy according to usual routine practice.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-12
Primary Completion
2030-06-25
Completion
2030-06-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07603856 on ClinicalTrials.gov